Deeter Investments
ENGN icon

Deeter Investments’s enGene Therapeutics ENGN Stock Holding History

Deeter Investments’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-90,000
Closed -$613K – 114
2026
Q1 		$613K Hold
90,000
– – 0.07% 89
2025
Q4 		$813K Buy
+90,000
New +$721K 0.17% 64

Other funds holding ENGN

FCPM III Services
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Nextech Invest
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ADAR1 Capital Management
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return

Deeter Investments's ENGN Position: Q2 2026 in Review

Deeter Investments sold out of enGene Therapeutics (ENGN) in Q2 2026, closing a stake of 90,000 shares — an estimated $613K sold.

Deeter Investments first reported a position in ENGN in Q4 2025 and held it in 2 quarters. The position peaked at $813K in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Deeter Investments reported no remaining enGene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Deeter Investments sold 90,000 enGene Therapeutics shares in Q2 2026, an estimated $613K.
  • Deeter Investments first reported a position in enGene Therapeutics in Q4 2025 and held it in 2 quarters.
  • Deeter Investments's enGene Therapeutics position peaked at $813K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Deeter Investments's 13F filing for Q2 2026, filed 8 Oct 2026.